Deep Genomics’ Post

"For our upcoming #obesity study, we're taking in the direct advice from #bigpharma to go for #quality rather than speed or cost" 🎯 In a business update with Mattias Vahlne from Infront Direkt Studios, CEO Gustav Hanghøj Gram H. Gram comments on the recent news of PILA PHARMA signing a contract with #Gubra to advance the company's #TRPV1 inhibitor in preclinical #obesity studies! 🌟 To watch the interview, please see the link in comments!

AbbVie ends its decade-long partnership with Calico Life Sciences, following the failure of their ALS treatment, and shifts focus away from small-molecule drugs to biologics and RNA therapies. What does this mean for longevity research and Calico’s future? #longevity #aging #biopharma #lifeSciences https://lnkd.in/gdUA83gK

Fantastic to see how FairJourney Biologics is harnessing the power of Cyto-Mine® Chroma to power their B Cell Discovery platform and accelerate antibody discovery. Cyto-Mine technology allows them to directly screen hundreds of thousands to half a million plasma cells within a single day to deliver faster functional hits for their customers. Proud to see our technology driving innovation in biologics development! Learn more about Cyto-Mine® Chroma: https://lnkd.in/gMW6aDrT #CytoMine Sphere Bio #AntibodyDiscovery #Biologics

Nine out of ten drugs that succeed in animals fail when tested in people. 💊 This isn't just a failure rate—it's a wake-up call for the entire pharmaceutical industry. #DART by Quantiphi is changing the game by replacing outdated animal models with AI-powered human stem cell systems. 🧬 Key Impacts: ✅ 60% faster biologics testing ✅ Millions saved in development costs ✅ Higher trial success rates ✅ FDA-aligned methodology Smarter testing today = stronger outcomes tomorrow. Transform your drug discovery process with DART 👉 https://lnkd.in/dJdjEat2 #DrugDiscovery #AI #Innovation #LifeSciences #DART #Quantiphi #SolvingWhatMatters

💥 Novartis acquires Avidity Biosciences, Inc.— #AOC is officially strategic Novartis has just announced it will acquire Avidity Biosciences, Inc. This marks a major signal for the Antibody–Oligonucleotide Conjugate (#AOC) modality — large pharma is no longer just partnering, it’s now buying the platform. 🔬 We mapped the global AOC pipeline (see chart). A few takeaways: Multiple AOC programs are now in Phase I–III for serious neuromuscular and rare diseases such as facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD). The field is being advanced by groups including Avidity Biosciences, Inc., Dyne Therapeutics, and Denali Therapeutics. China is entering the race. Companies such as ChainGen Bio are developing siRNA/AOC approaches for metabolic and neuromuscular targets — with their most advanced program already in Phase I clinical trial. 📩 If you are interested in licensing in assets from China, please feel free to contact us.   #BioPlusPartners #Innovation #BispecificAntibody #Healthcare #ChineseBiotech #Biotech #Antibody #Therapeutics #Antibodies #Mabs #Mab #Antibodydiscovery #Biologics #VC #LifeSciences #AntibodyOligonucleotideConjugate #AOC #Avidity

It was a distinct pleasure to spend an hour over video chat with Aviv Regev, Genentech's head of early R&D (gRED). In addition to the impressive tech and AI achievements she's been overseeing since 2020, I was struck when I asked her what leading gRED and she described a photo of a patient that had participated in a Phase I trial of the company's investigational oral selective estrogen receptor degrader (SERD), giredestrant (now in Phase III), holding a balloon with a number showing how many months they've lived on treatment. "You want to imagine one patient holding a balloon multiplied many, many, many, many, many times," she told me. That's what drives Regev's work, leading 2,400 researchers at gRED. She's betting that AI-driven drug discovery and the "Lab-in-the-Loop" can fundamentally change pharmaceutical R&D success rates. The early results are promising. AI now touches all of Genentech's antibody programs and one oncology program saw 25% faster lead optimization. AI generates novel chemical scaffolds that traditional methods wouldn't have found. But Regev stays grounded. "There's a ton of stuff that doesn't work," she admitted of pharma R&D writ large. "But you go for the stuff that you can make happen." For someone who discovered entirely new cell types (pulmonary ionocytes), co-founded the Human Cell Atlas, and pioneered #Perturbseq, the single-cell sequencing methodology underlying today's virtual cell efforts, that pragmatism feels earned. Read the full profile to learn about her journey from Tel Aviv to MIT to now shaping drug discovery at one of biotech's giants. #drugdiscovery #biotech #AI #pharma #leadership https://lnkd.in/g8AR9yxV

"In neuroscience, which investors often describe as a high-risk, high-reward area, Roche has veered toward collaborations and licensing agreements rather than all-out acquisitions. In 2023, it paid Ionis Pharmaceuticals, Inc. $60 million for rights to two RNA medicines meant to combat Alzheimer’s and Huntington’s. The following year, it licensed some technology from Sangamo Therapeutics, Inc. for another shot at an Alzheimer’s treatment, and partnered with an RNA editing specialist in a deal structured similarly to the Manifold pact." #biotech #deals #brainshuttles #BBB

Biogen is paying $70M upfront to Vanqua Bio for a preclinical oral C5aR1 drug — revisiting the same target it dropped after last year’s HI-Bio buyout. https://lnkd.in/ezCzbe_v

“Collaborating with MilliporeSigma allows us to push the boundaries of drug discovery,” said Thomas Livelli, VP, Life Sciences Products & Services at Promega Corporation . “By combining our technological strengths, we are helping to create more relevant and accessible models for drug discovery, with the goal of enabling new insights and eventually better outcomes for patients.” #MilliporeSigma #Promega #DrugDiscovery #3DCellModels #Organoids #NextGenBiology #AssayTechnology #HighThroughputScreening #BiotechPartnership #LifeSciencesInnovation https://lnkd.in/dqVXy9KK

Artis BioSolutions is proud to be a member of the BioMaP Consortium, a national initiative advancing U.S. biomanufacturing innovation and readiness. As part of this network, Artis and Landmark Bio are aligned with a national effort to expand innovation, capacity, and resilience in advanced therapy manufacturing. From viral vectors to cell therapy, we share BioMaP’s mission to accelerate technologies that bring next-generation medicines to patients faster and more reliably. 💡 Collaboration is how we build the future of biotech. Learn more about the BioMaP Consortium: https://hubs.la/Q03PC6kz0 #InnovationPartnerships #AdvancedTherapies #CGT #BioMaP #BioMaPConsortium